ACME Laboratories Ltd. Company Profile

Background

Founded in 1954 by Mr. Hamidur Rahman Sinha, ACME Laboratories Ltd. is a leading pharmaceutical company based in Dhaka, Bangladesh. The company's mission is to ensure health, vigor, and happiness for mankind by manufacturing world-class, top-quality pharmaceutical products. With over 70 years of expertise in medicine and science, ACME has established itself as a significant player in the pharmaceutical industry, producing more than 800 products across various dosage forms and therapeutic categories.

Key Strategic Focus

ACME Laboratories focuses on the manufacturing, marketing, and distribution of generic pharmaceutical formulation products. The company's portfolio includes human drugs in various dosage forms such as tablets, capsules, dry syrups, creams, ointments, powders, injections, dry powder inhalers, metered dosage inhalers, suppositories, eye and nasal drops, liquids, and sachet products. Additionally, ACME offers veterinary drugs and herbal products. The company targets both domestic and international markets, with a presence in regions including South East Asia, Africa, Central America, Europe, North America, and the CIS countries.

Financials and Funding

As of June 30, 2024, ACME Laboratories reported annual revenue of approximately $271.96 million USD, reflecting an 18.49% growth from the previous year. The company's net income grew by 6.62% during the same period. ACME is publicly traded on the Dhaka Stock Exchange under the ticker symbol ACMELAB.

Pipeline Development

ACME Laboratories has a robust pipeline of generic pharmaceutical products. In 2020, the company launched Zolpidem IR Tablet in the US market. In 2021, ACME received the prestigious WHO Prequalification approval for Zinc Dispersible Tablet. In 2023, the company received the stringent US FDA Approval and ANDA Approval for Chlorzoxazone Tablet and sANDA Approval for Zolpidem Tablet.

Technological Platform and Innovation

ACME Laboratories is committed to maintaining state-of-the-art manufacturing facilities to ensure the production of high-quality pharmaceutical products. The company's quality slogan, "Perpetual Quest for Excellence," reflects its dedication to continuous improvement and innovation. ACME has received various certifications, including ISO 9001:2015, WHO Prequalification, and approvals from regulatory bodies such as the US FDA, UK-MHRA, TGA Australia, and others.

Leadership Team

Mizanur Rahman Sinha: Chief Executive Officer and Managing Director since 1995.

Kazi Badruddin Mohammed: Director of Finance and Chief Financial Officer.

A. K. M. Mushiur Khan: Chief Administrative Officer since 1996.

Nagina Afzal Sinha: Chairperson since 2018.

Leadership Changes

In 2018, Nagina Afzal Sinha was appointed as Chairperson of ACME Laboratories Ltd.

Competitor Profile

Market Insights and Dynamics

The pharmaceutical industry in Bangladesh has been experiencing significant growth, driven by increasing domestic demand and expanding export opportunities. The market is characterized by a competitive landscape with several key players striving for market share.

Competitor Analysis

ACME Laboratories faces competition from both local and international pharmaceutical companies. Key competitors include:

Square Pharmaceuticals Ltd.: A leading pharmaceutical company in Bangladesh with a diverse product portfolio and strong market presence.

Beximco Pharmaceuticals Ltd.: Known for its wide range of generic pharmaceutical products and significant export activities.

Renata Limited: A prominent player in the Bangladeshi pharmaceutical market, focusing on both human and animal health products.

Strategic Collaborations and Partnerships

ACME Laboratories has engaged in various collaborations and partnerships to strengthen its market position and expand its capabilities. Notably, the company has received approvals from international regulatory bodies, enabling it to export products to markets such as the United States, United Kingdom, and Australia.

Operational Insights

ACME's strategic focus on quality and compliance with international standards has enabled it to compete effectively in both domestic and international markets. The company's commitment to innovation and expansion into new markets provides a competitive edge over its rivals.

Strategic Opportunities and Future Directions

ACME Laboratories aims to continue its expansion into international markets by obtaining further regulatory approvals and increasing its product portfolio. The company's ongoing investment in research and development, along with its focus on quality and innovation, positions it well to capitalize on emerging opportunities in the global pharmaceutical industry.